KORU Medical Systems Transition report pursuant to Rule 13a-10 or 15d-10

Transition report pursuant to Rule 13a-10 or 15d-10

STOCK-BASED COMPENSATION (Tables)

STOCK-BASED COMPENSATION (Tables)

10 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of fair value of the stock options granted Black-Scholes option valuation model

The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued:


	December 31, 2017		February 28, 2017

Dividend yield		0.00%		0.00%
Expected Volatility		70.1%-72.2%		59.00%-70.90%
Weighted-average volatility		—		—
Expected dividends		—		—
Expected term (in years)		5 Years		5 Years
Risk-free rate		2.30%-2.36%		2.17%-2.48%

Schedule of stock option plan

The following table summarizes the status of the Company’s stock option plan:


	December 31, 2017					February 28, 2017
	Shares		Weighted Average Exercise Price			Shares		Weighted Average Exercise Price

Outstanding at March 1		1,345,000	$	0.39			1,060,000	$	0.37
Granted		318,000	$	0.49			500,000	$	0.41
Exercised		—	$	—			—	$	—
Forfeited		625,000	$	0.39			215,000	$	0.36
Outstanding at year end		1,038,000	$	0.41			1,345,000	$	0.39
Options exercisable		737,010	$	0.38			—	$	—
Weighted average fair value of options granted during the period		—	$	0.29			—	$	0.21
Stock-based compensation expense		—	$	(4,417	)		—	$	115,828

Schedule of information pertaining to options outstanding

The following table presents information pertaining to options outstanding at December 31, 2017:


Range of Exercise Price	Number Outstanding	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price

$0.36-0.50	1,038,000	5 years	$	0.41	737,010	$	0.38